Clover Initiates Phase 2 Trial for RSV Vaccine, Enrolling 420 Participants
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: PRnewswire
- Trial Initiation: Clover Biopharmaceuticals has completed enrollment of the first participants in a Phase 2 clinical trial in Australia for its protein-based vaccine candidates SCB-1022 and SCB-1033, aiming to recruit up to 420 older adults aged 60 to 85 to assess vaccine safety and immunogenicity, thereby enhancing its global first-in-class potential.
- Combination Vaccine Advantage: The trial will evaluate SCB-1022 and SCB-1033, which target RSV and hMPV, with the latter also including PIV3, addressing significant unmet needs for vaccine protection globally, particularly for individuals previously vaccinated against RSV to restore their immunity.
- Validated Technology Platform: Clover's vaccine candidates utilize its validated Trimer-Tag technology platform, showcasing its innovative capabilities in vaccine development, which may significantly reduce the burden of vaccine-preventable diseases and strengthen its competitive position in the biotechnology sector.
- Global Market Potential: CEO Joshua Liang stated that the initiation of this Phase 2 trial represents a critical milestone in the company's R&D process and could open new growth opportunities in the vaccine market, particularly among the elderly population, enhancing the strategic importance of the company in the global vaccine landscape.
Analyst Views on 02197
Wall Street analysts forecast 02197 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 02197 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 2.900
Low
Averages
High
Current: 2.900
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
